Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.6K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity.

Journal of medicinal chemistry·2026
Same author

Spatial transcriptomic analyses highlight distinct erythroid niches in mice and humans.

Nature genetics·2026
Same author

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same author

<i>De novo</i> grafted coiled-coil peptides as p53/<i>h</i>DM2 inhibitors.

RSC chemical biology·2026
Same author

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Communications biology·2026
Same author

Orai1 is required for Ca<sup>2+</sup>-dependent plasma membrane repair and mechanoadaptation.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 15, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

167

PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.

Hongxia Chen1,2,3, Yunpeng Bai4, Michihiro Kobayashi5

  • 1Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.

Molecular Cancer Research : MCR
|September 27, 2023
PubMed
Summary

High expression of PRL2 (PTP4A2) drives acute myeloid leukemia (AML) by enhancing oncogenic KIT signaling. Inhibiting PRL2 reduces leukemia burden and improves survival in mice, identifying PRL2 as a potential therapeutic target for AML.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.3K

Related Experiment Videos

Last Updated: Jul 15, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

167
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Receptor tyrosine kinase KIT is frequently activated in acute myeloid leukemia (AML).
  • High PRL2 (Protein Phosphatase 4 catalytic subunit alpha 2) expression correlates with SCF/KIT signaling activation in AML, but the mechanism is unclear.

Purpose of the Study:

  • To investigate the role of PRL2 in oncogenic KIT signaling in AML.
  • To determine if PRL2 inhibition can be a therapeutic strategy for AML with KIT mutations.

Main Methods:

  • Inhibition of PRL2 in a mouse model of KIT-driven AML.
  • Analysis of KIT signaling pathways, including phosphorylation and ubiquitination.
  • Assessment of leukemic cell proliferation, survival, and mouse survival rates.

Main Results:

  • PRL2 inhibition significantly reduced leukemia burden and extended survival in leukemic mice.
  • PRL2 dephosphorylates CBL at tyrosine 371, inhibiting its activity towards KIT.
  • This leads to decreased KIT ubiquitination and enhanced AKT and ERK signaling in leukemia cells.

Conclusions:

  • PRL2 plays a critical role in enhancing oncogenic KIT signaling in AML.
  • PRL2 inhibition represents a promising therapeutic strategy for AML patients with KIT mutations.